Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 13, 2013, Pages 3826-3832

  Bell, Jessica L ^a   Haak, Andrew J ^b   Wade, Susan M ^b   Kirchhoff, Paul D ^a   Neubig, Richard R ^b,c   Larsen, Scott D ^a,c  

^a Department of Medicinal Chemistry   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anti metastasis; Cancer; Cell migration inhibition; Gene transcription inhibitor; MKL1; Rho; SRF

Indexed keywords

ANTIMETASTATIC AGENT; CCG 203971; MEGAKARYOCYTIC LEUKEMIA 1 PROTEIN; NOVEL NIPECOTIC BIS(AMIDE) INHIBITOR; PROTEIN; RHO FACTOR; SERUM RESPONSE FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CELL MIGRATION; CYTOTOXICITY; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY;

AMIDES; ANILIDES; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MOLECULAR STRUCTURE; NEOPLASM METASTASIS; NIPECOTIC ACIDS; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; RHOA GTP-BINDING PROTEIN; SERUM RESPONSE FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 84878828142     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.04.080     Document Type: Article

References (21)

1. A. Hakem, O. Sanchez-Sweatman, A. You-Ten, G. Duncan, A. Wakeham, R. Khokha, and T.W. Mak Genes Dev. 19 2005 1974
2. C. Mees, J. Nemunaitis, and N. Senzer Cancer Gene Ther. 16 2009 103
3. E.A. Clark, T.R. Golub, E.S. Lander, and R.O. Hynes Nature 406 2000 532
4. E. Sahai, and C.J. Marshall Nat. Rev. Cancer 2 2002 133
5. K.L. van Golen, Z.F. Wu, X.T. Qiao, L.W. Bao, and S.D. Merajver Cancer Res. 60 2000 5832
6. H. Yao, E.J. Dashner, C.M. van Golen, and K.L. van Golen Oncogene 25 2006 2285
7. C.R. Evelyn, S.M. Wade, Q. Wang, M. Wu, J.A. Iniguez-Lluhi, S.D. Merajver, and R.R. Neubig Mol. Cancer Ther. 6 2007 2249
8. R. Treisman Trends Biochem. Sci. 17 1992 423
9. B. Cen, A. Selvaraj, R.C. Burgess, J.K. Hitzler, Z. Ma, S.W. Morris, and R. Prywes Mol. Cell. Biol. 23 2003 6597
10. S. Medjkane, C. Perez-Sanchez, C. Gaggioli, E. Sahai, and R. Treisman Nat. Cell Biol. 11 2009 257
11. M. Prencipe, S.F. Madden, A. O'Neill, G. O'Hurley, A. Culhane, D. O'Connor, H. Klocker, E.W. Kay, W.M. Gallagher, and W.R. Watson Prostate 73 2013 743
12. C.R. Evelyn, S.M. Wade, Q. Wang, M. Wu, J.A. Iniguez-Lluhi, S.D. Merajver, and R.R. Neubig Mol. Cancer Ther. 6 2007 2249
13. C.R. Evelyn, J.L. Bell, J.G. Ryu, S.M. Wade, A. Kocab, N.L. Harzdorf, H.D. Hollis Showalter, R.R. Neubig, and S.D. Larsen Bioorg. Med. Chem. Lett. 20 2010 665
14. R.T. Jacob, M.J. Larsen, S.D. Larsen, P.D. Kirchhoff, D.H. Sherman, and R.R. Neubig J. Biomol. Screen. 17 2012 1080
15. R.M. Lawrence, S.A. Biller, O.M. Fryszman, and M.A. Poss Synthesis 1997 1997 553
16. B.J. Leslie, and P.J. Hergenrother Chem. Soc. Rev. 37 2008 1347
17. E.H. Kerns, and L. Di Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization 2008 Academic Press Amsterdam; Boston p 292
18. M. Uehata, T. Ishizaki, H. Satoh, T. Ono, T. Kawahara, T. Morishita, H. Tamakawa, K. Yamagami, J. Inui, M. Maekawa, and S. Narumiya Nature 389 1997 990
19. A.V. Somlyo, D. Bradshaw, S. Ramos, C. Murphy, C.E. Myers, and A.P. Somlyo Biochem. Biophys. Res. Commun. 269 2000 652
20. E. Vial, E. Sahai, and C.J. Marshall Cancer Cell 4 2003 67
21. K.J. Jeong, S.Y. Park, K.H. Cho, J.S. Sohn, J. Lee, Y.K. Kim, J. Kang, C.G. Park, J.W. Han, and H.Y. Lee Oncogene 31 2012 4279